64 related articles for article (PubMed ID: 36319669)
1. Integrative analysis with machine learning identifies diagnostic and prognostic signatures in neuroblastoma based on differentially DNA methylated enhancers between INSS stage 4 and 4S neuroblastoma.
Li S; Mi T; Jin L; Liu Y; Zhang Z; Wang J; Wu X; Ren C; Wang Z; Kong X; Liu J; Luo J; He D
J Cancer Res Clin Oncol; 2024 Mar; 150(3):148. PubMed ID: 38512513
[TBL] [Abstract][Full Text] [Related]
2.
Zhang X; Wang B; Lin L; Zhou C; Zhu J; Wu H; He J
Heliyon; 2024 Mar; 10(6):e27988. PubMed ID: 38509981
[TBL] [Abstract][Full Text] [Related]
3. Construction of methylation driver gene-related prognostic signature and development of a new prognostic stratification strategy in neuroblastoma.
Han Y; Li B; Cheng J; Zhou D; Yuan X; Zhao W; Zhang D; Zhang J
Genes Genomics; 2024 Feb; 46(2):171-185. PubMed ID: 38180715
[TBL] [Abstract][Full Text] [Related]
4. Identification of the ultrahigh-risk subgroup in neuroblastoma cases through DNA methylation analysis and its treatment exploiting cancer metabolism.
Watanabe K; Kimura S; Seki M; Isobe T; Kubota Y; Sekiguchi M; Sato-Otsubo A; Hiwatari M; Kato M; Oka A; Koh K; Sato Y; Tanaka H; Miyano S; Kawai T; Hata K; Ueno H; Nannya Y; Suzuki H; Yoshida K; Fujii Y; Nagae G; Aburatani H; Ogawa S; Takita J
Oncogene; 2022 Nov; 41(46):4994-5007. PubMed ID: 36319669
[TBL] [Abstract][Full Text] [Related]
5. Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma.
Eberhardt A; Hansen JN; Koster J; Lotta LT; Wang S; Livingstone E; Qian K; Valentijn LJ; Zheng YG; Schor NF; Li X
Oncotarget; 2016 Sep; 7(39):63629-63639. PubMed ID: 27571165
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with the CDK7 inhibitor and the tyrosine kinase inhibitor exerts synergistic anticancer effects against MYCN-amplified neuroblastoma.
Tee AE; Ciampa OC; Wong M; Fletcher JI; Kamili A; Chen J; Ho N; Sun Y; Carter DR; Cheung BB; Marshall GM; Liu PY; Liu T
Int J Cancer; 2020 Oct; 147(7):1928-1938. PubMed ID: 32086952
[TBL] [Abstract][Full Text] [Related]
7. A Novel MYCN-Specific Antigene Oligonucleotide Deregulates Mitochondria and Inhibits Tumor Growth in MYCN-Amplified Neuroblastoma.
Montemurro L; Raieli S; Angelucci S; Bartolucci D; Amadesi C; Lampis S; Scardovi AL; Venturelli L; Nieddu G; Cerisoli L; Fischer M; Teti G; Falconi M; Pession A; Hrelia P; Tonelli R
Cancer Res; 2019 Dec; 79(24):6166-6177. PubMed ID: 31615807
[TBL] [Abstract][Full Text] [Related]
8. Predicting amplification of
Giwa A; Rossouw SC; Fatai A; Gamieldien J; Christoffels A; Bendou H
Future Oncol; 2021 Dec; 17(34):4769-4783. PubMed ID: 34751044
[TBL] [Abstract][Full Text] [Related]
9. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group.
Irwin MS; Naranjo A; Zhang FF; Cohn SL; London WB; Gastier-Foster JM; Ramirez NC; Pfau R; Reshmi S; Wagner E; Nuchtern J; Asgharzadeh S; Shimada H; Maris JM; Bagatell R; Park JR; Hogarty MD
J Clin Oncol; 2021 Oct; 39(29):3229-3241. PubMed ID: 34319759
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting phosphoglycerate dehydrogenase counteracts chemotherapeutic efficacy against MYCN-amplified neuroblastoma.
Arlt B; Zasada C; Baum K; Wuenschel J; Mastrobuoni G; Lodrini M; Astrahantseff K; Winkler A; Schulte JH; Finkler S; Forbes M; Hundsdoerfer P; Guergen D; Hoffmann J; Wolf J; Eggert A; Kempa S; Deubzer HE
Int J Cancer; 2021 Mar; 148(5):1219-1232. PubMed ID: 33284994
[TBL] [Abstract][Full Text] [Related]
11. Integrated multiomics analysis of hepatoblastoma unravels its heterogeneity and provides novel druggable targets.
Sekiguchi M; Seki M; Kawai T; Yoshida K; Yoshida M; Isobe T; Hoshino N; Shirai R; Tanaka M; Souzaki R; Watanabe K; Arakawa Y; Nannya Y; Suzuki H; Fujii Y; Kataoka K; Shiraishi Y; Chiba K; Tanaka H; Shimamura T; Sato Y; Sato-Otsubo A; Kimura S; Kubota Y; Hiwatari M; Koh K; Hayashi Y; Kanamori Y; Kasahara M; Kohashi K; Kato M; Yoshioka T; Matsumoto K; Oka A; Taguchi T; Sanada M; Tanaka Y; Miyano S; Hata K; Ogawa S; Takita J
NPJ Precis Oncol; 2020; 4():20. PubMed ID: 32656360
[TBL] [Abstract][Full Text] [Related]
12. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type.
Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG
Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
